Skip to main content
NewslettersWatchlist

Merus N.V. CS(MRUS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low53.38
Day High55.39
Open:53.44
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Newswire.ca
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates
BayStreet.ca
Biotech Innovations Poised to Transform Pancreatic Cancer Treatment and Patient Outcomes
Newswire.ca
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates
BayStreet.ca
Biotech Developers Pioneer New Treatments, Aiming to Reduce Pancreatic Cancer Fatalities in 2024
BayStreet.ca
Pancreatic Cancer Battle Intensifies with Biotech Sector's Advanced Treatments
BayStreet.ca
Breakthroughs in Pancreatic Cancer Treatment: How FDA Designations are Changing the Game
Globe Newswire
Merus Announces Financial Results for the Second Quarter and Provides Business Update
Globe Newswire
Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract)
Globe Newswire
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference
Globe Newswire
Merus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Globe Newswire
Merus to Present at the H.C. Wainwright Global Investment Conference
Globe Newswire
Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update
Globe Newswire
Merus Announces Publication in Nature Cancer on Petosemtamab’s (MCLA-158) Unique Mechanism of Action
Globe Newswire
Merus Presents Preclinical Data on MCLA-129 at the American Association for Cancer Research Annual Meeting 2022
Globe Newswire
Merus to Participate in a Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
Business Wire
Rallybio Appoints Christine A. Nash and Hui Liu, Ph.D., to Its Board of Directors
Globe Newswire
Merus Announces Publication of Abstract on MCLA-129 at the American Association for Cancer Research 2022 Annual Meeting
Globe Newswire
Merus Announces Financial Results for the Fourth Quarter and Full Year 2021 and Provides Business Update
Globe Newswire
Merus to Participate in Upcoming Investor Conferences
Globe Newswire
Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145
BayStreet.ca
Biotech Sector Answering Calls for New Breast Cancer Treatment Developments in 2022
Globe Newswire
Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

Profile

Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.